204 related articles for article (PubMed ID: 38231412)
1. Allogeneic CAR-T cells with of HLA-A/B and TRAC disruption exhibit promising antitumor capacity against B cell malignancies.
Chen X; Tan B; Xing H; Zhao X; Ping Y; Zhang Z; Huang J; Shi X; Zhang N; Lin B; Cao W; Li X; Zhang X; Li L; Jiang Z; Zhang M; Li W; Liu M; Du B; Zhang Y
Cancer Immunol Immunother; 2024 Jan; 73(1):13. PubMed ID: 38231412
[TBL] [Abstract][Full Text] [Related]
2. CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia.
Hu Y; Zhou Y; Zhang M; Ge W; Li Y; Yang L; Wei G; Han L; Wang H; Yu S; Chen Y; Wang Y; He X; Zhang X; Gao M; Yang J; Li X; Ren J; Huang H
Clin Cancer Res; 2021 May; 27(10):2764-2772. PubMed ID: 33627493
[TBL] [Abstract][Full Text] [Related]
3. [Maintenance therapy following CD19 CAR-T treatment for relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].
Jiang YL; Li Q; Pu YD; Jiang YY; Yuan T; Deng Q; Li YM; Han MZ; Zhai WH
Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):495-501. PubMed ID: 32654464
[No Abstract] [Full Text] [Related]
4. Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease.
Brudno JN; Somerville RP; Shi V; Rose JJ; Halverson DC; Fowler DH; Gea-Banacloche JC; Pavletic SZ; Hickstein DD; Lu TL; Feldman SA; Iwamoto AT; Kurlander R; Maric I; Goy A; Hansen BG; Wilder JS; Blacklock-Schuver B; Hakim FT; Rosenberg SA; Gress RE; Kochenderfer JN
J Clin Oncol; 2016 Apr; 34(10):1112-21. PubMed ID: 26811520
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia.
Ottaviano G; Georgiadis C; Gkazi SA; Syed F; Zhan H; Etuk A; Preece R; Chu J; Kubat A; Adams S; Veys P; Vora A; Rao K; Qasim W;
Sci Transl Med; 2022 Oct; 14(668):eabq3010. PubMed ID: 36288281
[TBL] [Abstract][Full Text] [Related]
6. Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy.
Chen W; Ma Y; Shen Z; Chen H; Ma R; Yan D; Shi M; Wang X; Song X; Sun C; Cao J; Cheng H; Zhu F; Sun H; Li D; Li Z; Zheng J; Xu K; Sang W
Front Immunol; 2021; 12():755549. PubMed ID: 34777367
[TBL] [Abstract][Full Text] [Related]
7. Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers.
Blanco B; Ramírez-Fernández Á; Bueno C; Argemí-Muntadas L; Fuentes P; Aguilar-Sopeña Ó; Gutierrez-Agüera F; Zanetti SR; Tapia-Galisteo A; Díez-Alonso L; Segura-Tudela A; Castellà M; Marzal B; Betriu S; Harwood SL; Compte M; Lykkemark S; Erce-Llamazares A; Rubio-Pérez L; Jiménez-Reinoso A; Domínguez-Alonso C; Neves M; Morales P; Paz-Artal E; Guedan S; Sanz L; Toribio ML; Roda-Navarro P; Juan M; Menéndez P; Álvarez-Vallina L
Cancer Immunol Res; 2022 Apr; 10(4):498-511. PubMed ID: 35362043
[TBL] [Abstract][Full Text] [Related]
8. Universal allogeneic CAR T cells engineered with Sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapy.
Tipanee J; Samara-Kuko E; Gevaert T; Chuah MK; VandenDriessche T
Mol Ther; 2022 Oct; 30(10):3155-3175. PubMed ID: 35711141
[TBL] [Abstract][Full Text] [Related]
9. [Safety and efficacy of humanized CD19-targeted CAR-T cells in patients with relapsed/refractory acute B cell lymphoblastic leukemia].
Song FM; Hu YX; Zhang MM; Wu WW; Xu HJ; Zhang HS; Huang H; Wei GQ
Zhonghua Xue Ye Xue Za Zhi; 2022 Aug; 43(8):651-656. PubMed ID: 36709149
[No Abstract] [Full Text] [Related]
10. Impact of Consolidative Unrelated Cord Blood Transplantation on Clinical Outcomes of Patients With Relapsed/Refractory Acute B Lymphoblastic Leukemia Entering Remission Following CD19 Chimeric Antigen Receptor T Cells.
Xu Q; Xue L; An F; Xu H; Wang L; Geng L; Zhang X; Song K; Yao W; Wan X; Tong J; Liu H; Liu X; Zhu X; Zhai Z; Sun Z; Wang X
Front Immunol; 2022; 13():879030. PubMed ID: 35558072
[TBL] [Abstract][Full Text] [Related]
11. Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia.
Roddie C; Dias J; O'Reilly MA; Abbasian M; Cadinanos-Garai A; Vispute K; Bosshard-Carter L; Mitsikakou M; Mehra V; Roddy H; Hartley JA; Spanswick V; Lowe H; Popova B; Clifton-Hadley L; Wheeler G; Olejnik J; Bloor A; Irvine D; Wood L; Marzolini MAV; Domning S; Farzaneh F; Lowdell MW; Linch DC; Pule MA; Peggs KS
J Clin Oncol; 2021 Oct; 39(30):3352-3363. PubMed ID: 34464155
[TBL] [Abstract][Full Text] [Related]
12. [Allogeneic donor-derived CD19 CAR-T therapy of relapsed B-cell acute lmphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].
Ma RZ; He Y; Yang DL; Wei JL; Pang AM; Jiang EL; Wang JX; Han MZ; Zhang RL; Feng SZ
Zhonghua Xue Ye Xue Za Zhi; 2021 May; 42(5):383-389. PubMed ID: 34218580
[No Abstract] [Full Text] [Related]
13. [Safety and efficacy of patients with refractory B-lymphoblastic leukemia treated with anti-CD19 CAR-T cell bridging to allogeneic hematopoietic stem cell transplantation].
Ai H; Yin QS; Wang Q; Fu YW; Wei XD; Song YP
Zhonghua Xue Ye Xue Za Zhi; 2020 Mar; 41(3):239-244. PubMed ID: 32311895
[No Abstract] [Full Text] [Related]
14. Allogeneic, donor-derived, second-generation, CD19-directed CAR-T cells for the treatment of pediatric relapsed/refractory BCP-ALL.
Del Bufalo F; Becilli M; Rosignoli C; De Angelis B; Algeri M; Hanssens L; Gunetti M; Iacovelli S; Li Pira G; Girolami E; Leone G; Lazzaro S; Bertaina V; Sinibaldi M; Di Cecca S; Iaffaldano L; Künkele A; Boccieri E; Del Baldo G; Pagliara D; Merli P; Carta R; Quintarelli C; Locatelli F
Blood; 2023 Jul; 142(2):146-157. PubMed ID: 37172203
[TBL] [Abstract][Full Text] [Related]
15. Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemotherapy-Based Complete Remission in B-Cell Acute Lymphoblastic Leukemia.
Zhao YL; Liu DY; Sun RJ; Zhang JP; Zhou JR; Wei ZJ; Xiong M; Cao XY; Lu Y; Yang JF; Zhang X; Lu DP; Lu P
Front Immunol; 2021; 12():605766. PubMed ID: 34025637
[TBL] [Abstract][Full Text] [Related]
16. Case Report: Successful engraftment of allogeneic hematopoietic stem cells using CAR-T cell therapy as the conditioning regimen in R/R Ph
Han L; Zhao R; Yang J; Zu Y; Liu Y; Zhou J; Li L; Huang Z; Zhang J; Gao Q; Song Y; Zhou K
Front Immunol; 2022; 13():965932. PubMed ID: 36225940
[TBL] [Abstract][Full Text] [Related]
17. CD19 CAR-T Cells With Membrane-Bound IL-15 for B-Cell Acute Lymphoblastic Leukemia After Failure of CD19 and CD22 CAR-T Cells: Case Report.
Sun Y; Su Y; Wang Y; Liu N; Li Y; Chen J; Qiao Z; Niu J; Hu J; Zhang B; Ning H; Hu L
Front Immunol; 2021; 12():728962. PubMed ID: 34691036
[TBL] [Abstract][Full Text] [Related]
18. [Long-term follow-up of humanized and murine CD19 CAR-T-cell therapy for B-cell acute lymphoblastic leukemia].
Du MY; Zhang YQ; Liao DY; Xie W; Xiong W; Mei H; Hu Y
Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):793-799. PubMed ID: 38049329
[No Abstract] [Full Text] [Related]
19. Detection of CAR-T19 cells in peripheral blood and cerebrospinal fluid: An assay applicable to routine diagnostic laboratories.
Johansson U; Gallagher K; Burgoyne V; Maus MV; Casey KS; Brini GG; Frigault MJ; Yam JY; Chavda N; Besley C; Lugthart S
Cytometry B Clin Cytom; 2021 Nov; 100(6):622-631. PubMed ID: 33915021
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic Donor-Derived Anti-CD19 CAR T Cell Is a Promising Therapy for Relapsed/Refractory B-ALL After Allogeneic Hematopoietic Stem-Cell Transplantation.
Hua J; Zhang J; Wu X; Zhou L; Bao X; Han Y; Miao M; Li C; Fu Z; Wu D; Qian W; Qiu H
Clin Lymphoma Myeloma Leuk; 2020 Sep; 20(9):610-616. PubMed ID: 32507386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
